Back to News
May 5, 2026 12:01 PM

Eli Lilly Advances As Inflammatory Bowel Disease Drug Reinforces Long-Term Confidence

Eli Lilly and Co. (NYSE:LLY) shares are trading higher on Tuesday as the company is reporting new data on its treatment for ulcerative colitis (UC).

Omvoh Shows Durable Disease Clearance

Disease clearance was evaluated among patients who achieved clinical remission with Omvoh at one year in the LUCENT-2 maintenance study and continued treatment in LUCENT-3, an open-label extension study.

Eli Lilly’s recent data from the LUCENT-3 clinical trial shows that over 63.5% of patients treated with Omvoh (mirikizumab-mrkz) maintained disease clearance after four years.

This is a significant milestone, as it marks the first time an interleukin-23p19 inhibitor has demonstrated such durable disease clearance in patients with UC.

Read Also:

Eli Lilly Jumps As Earnings Beat ...